Cargando…
Radioembolization for Hepatocellular Carcinoma using TheraSphere(®)
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y90) microspheres is a new concept in radiation therapy for HCC. This review focuses on the indications, efficacy, side effects, and future direction of Y90 therapy,...
Autor principal: | Ali, Safiyya Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122095/ https://www.ncbi.nlm.nih.gov/pubmed/21546728 http://dx.doi.org/10.4103/1319-3767.80388 |
Ejemplares similares
-
Cost-effectiveness analysis of personalised versus standard dosimetry for selective internal radiation therapy with TheraSphere in patients with hepatocellular carcinoma
por: Rognoni, Carla, et al.
Publicado: (2022) -
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial
por: Chauhan, Nikhil, et al.
Publicado: (2018) -
TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial
por: Chauhan, Nikhil, et al.
Publicado: (2019) -
ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs)
por: Sharma, Rohini, et al.
Publicado: (2022) -
Radioembolization for the treatment of hepatocellular carcinoma
por: Kim, Hyo-Cheol
Publicado: (2017)